Dingfu Biotarget Co., Ltd.
Records under this name other than patents Dingfu Biotarget Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Dingfu Biotarget Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,471,124 | Proteinaceous heterodimer and use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,357,826 | IL-10 EGFR antibody fusion protein and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,624,974 | Anti-OX40 antibody and application thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,875,926 | Fully human antibody against human CD 137 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,795,230 | ANTI-CD27 Antibodies and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,529,425 | Immunoconjugates comprising signal regulatory protein alpha Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,845,806 | Proteinaceous heterodimer and use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,987,609 | Proteinaceous heterodimer and use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,883,503 | Methods and compositions for cancer treatment Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,252,542 | Anti-CD137 antibodies and method of treating colorectal cancer using them Formerly held In force · From the USPTO record | In force | From the USPTO record |